|
|
|
|
|
07.05.26 - 23:21
|
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that its board of directors authorized the repurchase of an additional $2 billion of IQVIA's common stock under IQVIA's existing equity repurchase program (the “Repurchase Program”), bringing the total remaining authorization to $3.2 billion.
The Repurchase Program does not obligate IQVIA to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time. The timing and amount of repurchases are determined by IQVIA's management based on a variety of factors such as the market price of IQVIA's common stock, IQVIA's corporate requirements, and overall market conditions. Purchases of IQVIA's common stock may be made in open market transactions effected through a broker-dealer at preva...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.05.26 - 13:24
|
IQVIA Holdings Inc. Profit Climbs In Q1 (AFX)
|
|
|
WASHINGTON (dpa-AFX) - IQVIA Holdings Inc. (IQV) revealed earnings for its first quarter that Increases, from the same period last yearThe company's bottom line totaled $274 million, or $1.61 per ......
|
|
|
05.05.26 - 13:06
|
IQVIA Reports First-Quarter 2026 Results (Business Wire)
|
|
|
Revenue of $4,151 million, up 8.4% year-over-year
GAAP Net Income of $274 million, Adjusted EBITDA of $932 million
GAAP Diluted Earnings per Share of $1.61, Adjusted Diluted Earnings per Share of $2.90
Commercial Solutions Revenue of $1,754 million, up 11.6% reported year-over-year
R&D Solutions Revenue of $2,397 million, up 6.2% reported year-over-year
R&D Solutions contracted backlog of $34.2 billion, R&D Solutions Net New Bookings of $2.5 billion
Operating Cash Flow of $618 million; Free Cash Flow of $491 million, up 15% year-over-year, representing 100% of Adjusted Net Income
Repurchased $552 million of IQVIA common stock
Reaffirming full-year 2026 guidance for revenue and Adjusted EBITDA; raising full-year 2026 guidance for Adjusted Diluted Earnings per Share to $12.65 - $12.95
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and hea...
|
|
|
|
|
|
|
24.04.26 - 15:39
|
Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street (ZeroHedge)
|
|
|
Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street
Shares of Eli Lilly & Co. fell in New York premarket trading after new industry prescription data for the drugmaker's blockbuster obesity shot Zepbound and recently approved oral weight-loss pill Foundayo disappointed Wall Street analysts.
Foundayo generated 3,707 prescriptions in its second week, according to new prescription-tracking data from IQVIA cited by RBC Capital Markets analysts. That compares with 18,410 prescriptions for Novo's oral version of Wegovy during its second week after launch, suggesting Lilly's weight-loss drugs are falling behind in the GLP-1 race.
"While we believe comparisons early into launch should be considered immaterial, Foundayo's uptake this week is likely to be received negatively," RBC Capital Markets analyst Trung Huynh wrote in a note to clients earlier.
In a separate note citing the IQVIA data, Cantor analyst Carter Gould said, "We see slower TRx (total prescriptions) growth ...
|
|
|
|
|
17.04.26 - 17:12
|
XETR: Deletion of Instruments from XETRA - 17.04.2026 -1- (XETRA)
|
|
|
The following instruments on XETRA do have their last trading day on 17.04.2026.
Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.
ISIN Name
US0028962076 Abercrombie & Fitch Co.
US0162551016 Align Technology Inc.
US02043Q1076 Alnylam Pharmaceuticals Inc.
US0255371017 American Electric Power Co. Inc.
US0311001004 AMETEK Inc.
US0530151036 Automatic Data Processing Inc.
GB00BPQY8M80 Aviva PLC
IE00BD1RP616 Bank of Ireland Group PLC
US14448C1045 Carrier Global Corp.
US8085131055 Charles Schwab Corp.
US16119P1084 Charter Communications Inc. [Del.]
US1713401024 Church & Dwight Co. Inc.
US1255231003 Cigna Group, The
US1729081059 Cintas Corp.
US12572Q1058 CME Group Inc.
US1924461023 Cognizant Technology Solutions Corp.
US2091151041 Consolidated Edison Inc.
US22052L1044 Corteva Inc.
US1264081035 CSX Corp.
US2310211063 Cummins Inc.
US2435371073 Deckers Outdoor Corp.
DK0060738599 Demant AS
US2533931026 Dics Sporting Goods Inc.
US2566771059 Dollar General Co...
|
|
|
|
|
15.04.26 - 22:18
|
IQVIA to Announce First-Quarter 2026 Results on May 5, 2026 (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com.
To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance at http://ir.iqvia.com. Following registration for the call, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a uniq...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
